title: Clinical characteristics, treatment, and outcome of dogs with presumed primary hepatic lymphoma: 18 cases (1992-2008).
abstract: OBJECTIVE-To determine outcome of dogs with presumed primary hepatic lymphoma treated with various multiagent, doxorubicin-based chemotherapeutic protocols and identify factors associated with prognosis. DESIGN-Retrospective case series. ANIMALS-18 dogs with presumed primary hepatic lymphoma. PROCEDURES-Medical records were reviewed for information on signalment, treatment, and outcome. RESULTS-8 dogs had a complete remission (CR), with a median remission duration of 120 days. Dogs with leukocytosis, neutrophilia, hypoalbuminemia, hyperbilirubinemia, or a combination of hypoalbuminemia and hyperbilirubinemia were less likely to achieve a CR. Overall median survival time (MST) was 63 days (range, 2 to 402 days). In a multivariate analysis, response to treatment and serum albumin concentration were associated with MST. Dogs that did not achieve a CR had a significantly shorter MST than did dogs that did achieve a CR (13 vs 283 days, respectively). Dogs with serum albumin concentration < 2.5 g/dL at the time treatment was initiated had a significantly shorter MST than did dogs with serum albumin concentration within reference limits (10 vs 128 days, respectively). There was also a positive correlation between serum albumin concentration and survival time (r = 0.74). CONCLUSIONS AND CLINICAL RELEVANCE-Results suggested that dogs with primary hepatic lymphoma that underwent chemotherapy had a poor prognosis, with a low response rate. Dogs that responded to treatment had a better prognosis, and dogs with hypoalbuminemia had a poorer prognosis.
authors.affiliation: School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot 76100, Israel. dank@agri.huji.ac.il
authors.forename: Gillian
authors.initials: G
authors.lastname: Dank
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Rassnick
authors.forename: Orna
authors.initials: O
authors.lastname: Kristal
authors.forename: Carlos O
authors.initials: CO
authors.lastname: Rodriguez
authors.forename: Craig A
authors.initials: CA
authors.lastname: Clifford
authors.forename: Rebecca
authors.initials: R
authors.lastname: Ward
authors.forename: Courtney L
authors.initials: CL
authors.lastname: Mallett
authors.forename: Tracy
authors.initials: T
authors.lastname: Gieger
authors.forename: Gilad
authors.initials: G
authors.lastname: Segev
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D005260:Female; D008113:Liver Neoplasms / Q000628:therapy / Q000662:veterinary*; D008223:Lymphoma / Q000628:therapy / Q000662:veterinary*; D008297:Male; D012189:Retrospective Studies